ObsEva to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
ObsEva SA (NASDAQ: OBSV; SIX: OBSN) announced a corporate update and investor meetings at the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
ObsEva SA (NASDAQ: OBSV; SIX: OBSN) announced a corporate update and investor meetings at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. The presentation will be accessible on-demand from 7:00 a.m. ET on September 13, via the conference portal. ObsEva focuses on developing therapies for women’s reproductive health, with a late-stage clinical pipeline addressing issues like endometriosis and preterm labor.
Details
News Market Reaction – OBSV
The recorded move for OBSV in the trading session of this news was -2.22%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
GENEVA, Switzerland September 7, 2021 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced that Company Management will provide a corporate update and participate in one-on-one investor meetings at the H.C. Wainwright 23rd Annual Global Investment Conference to be held September 13-15, 2021.
The presentation will be available on-demand through the H.C. Wainwright conference portal, starting at 7:00 a.m. ET on Monday, September 13, 2021.
The presentation and archived webcast will also be accessible under "Events Calendar" in the investors section of ObsEva's website.
About ObsEva
ObsEva is a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids and preterm labor. ObsEva is listed on the NASDAQ Global Select Market and is trading under the ticker symbol “OBSV” and on the SIX Swiss Exchange where it is trading under the ticker symbol “OBSN”. For more information, please visit www.ObsEva.com.
For further information, please contact:
CEO Office contact
Shauna Dillon
Shauna.dillon@obseva.ch
+41 22 552 1550
Investor Contact
Joyce Allaire
jallaire@lifesciadvisors.com
+1 (617) 435-6602
Attachment
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.